Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP trimmed its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 79.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 53,500 shares of the company's stock after selling 202,900 shares during the period. Two Sigma Advisers LP owned approximately 0.14% of Tarsus Pharmaceuticals worth $2,962,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Paradigm Biocapital Advisors LP raised its holdings in shares of Tarsus Pharmaceuticals by 3.7% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 2,531,896 shares of the company's stock worth $140,191,000 after purchasing an additional 91,451 shares during the last quarter. Jennison Associates LLC grew its position in Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock worth $138,432,000 after purchasing an additional 321,552 shares during the period. Vanguard Group Inc. raised its stake in shares of Tarsus Pharmaceuticals by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 2,115,162 shares of the company's stock valued at $117,117,000 after buying an additional 17,839 shares during the last quarter. Toronto Dominion Bank acquired a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $105,714,000. Finally, Lord Abbett & CO. LLC boosted its stake in shares of Tarsus Pharmaceuticals by 115.2% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock worth $70,873,000 after buying an additional 685,111 shares during the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TARS has been the topic of several analyst reports. Guggenheim raised their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Jefferies Financial Group raised their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Barclays cut their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. The Goldman Sachs Group increased their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a report on Monday, May 5th. Finally, HC Wainwright upgraded shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price target on the stock in a research report on Tuesday, May 27th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $66.17.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock traded down $0.50 during trading on Friday, reaching $42.94. The company had a trading volume of 428,338 shares, compared to its average volume of 702,325. The firm has a market capitalization of $1.80 billion, a PE ratio of -11.27 and a beta of 0.94. The firm's 50-day simple moving average is $46.93 and its 200 day simple moving average is $48.96. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $78.34 million during the quarter, compared to analysts' expectations of $72.50 million. As a group, equities research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Bobak R. Azamian sold 8,534 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $427,638.74. Following the completion of the sale, the chief executive officer now directly owns 53,635 shares in the company, valued at approximately $2,687,649.85. The trade was a 13.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Bryan Wahl sold 3,341 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the transaction, the general counsel now directly owns 58,057 shares of the company's stock, valued at approximately $2,687,458.53. This represents a 5.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,542 shares of company stock worth $1,581,173. Insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.